CLX vs INBX · P/E 15, rev $7.10B vs rev $1.3M
The Clorox Company (CLX) versus Inhibrx Biosciences, Inc. (INBX) — a side-by-side from cached financials, not a winner call.
The Clorox Company (CLX) is a household & personal products company listed on US.
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
Latest reported CLX revenue for 2025-06-30 was $7.10B. Net income was $824.0M. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
CLX currently screens at market cap $10.89B and trailing P/E 14.6. INBX currently screens at market cap $1.28B.
Not investment advice. Open the CLX and INBX stock pages for the full models.
Not investment advice.